Weekly metabolic injections must yield to monthly and long-acting clinical alternatives.
To solve chronic patient non-adherence and escape competitive weekly pricing pressure, the obesity market is rapidly shifting toward monthly injectables and semi-annual subdermal implants.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
The monthly-dosing challenger attacks the weekly incumbents' installed base directly with a registrational switch study.
A first-in-class monthly agonist with maintenance data showing efficacy preserved after the weekly-to-monthly switch is being scaled straight into Phase 3.
Viking's clinical study actively explores maintenance regimens that transition patients away from weekly injections toward less frequent monthly and oral alternatives.
It highlights the clinical shift toward ultra-long-acting once-monthly dosing options to bypass the adherence challenges and pricing pressures of weekly injections.
The weekly-injection incumbent itself is evaluating once- or twice-yearly delivery to escape chronic-therapy non-adherence.
Pfizer killed its oral assets to build a ten-trial Phase 3 program around monthly dosing, institutionalizing the shift from weekly injections to long-acting regimens.